- Motley Fool•8 hours ago
A big phase 3 win for its up-and-coming multiple sclerosis drug could clear the path to billions of dollars in additional annual sales for this big-cap biotech stock.
- Market Realist•2 days ago
Sanofi reported a sequential revenue growth of ~3.4% at constant exchange rates for 4Q16.
- Motley Fool•3 days ago
News that Amgen's Repatha lowers the risk of major cardiovascular events could clear the way for this medicine to achieve billion-dollar blockbuster status.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||43.06 - 43.33|
|52 Week Range||36.81 - 44.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.95|
|Dividend & Yield||1.66 (3.85%)|
|1y Target Est||N/A|